Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Launch date
Employees
Market cap
AUD3.8m
Enterprise valuation
AUD200m (Public information from Sep 2024)
Share price
$0.006 SRNE
San Diego California (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 152m | 21.0m | 31.0m | 40.0m | 53.0m | 63.0m | 211m |
| % growth | - | (86 %) | 48 % | 29 % | 33 % | 19 % | - |
| EBITDA | 59.0m | (121m) | (184m) | (191m) | (356m) | (365m) | - |
| % EBITDA margin | 39 % | (576 %) | (594 %) | (478 %) | (672 %) | (579 %) | - |
| Profit | 9.0m | (204m) | (292m) | (298m) | (428m) | (573m) | - |
| % profit margin | 6 % | (971 %) | (942 %) | (745 %) | (808 %) | (910 %) | - |
| EV / revenue | 1.8x | 16.6x | 25.2x | 46.4x | 29.0x | 7.9x | - |
| EV / EBITDA | 4.6x | -2.9x | -4.2x | -9.7x | -4.3x | -1.4x | - |
| R&D budget | 50.6m | 73.7m | 105m | 111m | 207m | 221m | - |
| R&D % of revenue | 33 % | 351 % | 337 % | 278 % | 390 % | 351 % | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $2.3m | Early VC | |
| N/A | $30.0m | IPO | |
| N/A | $2.0m | Early VC | |
| N/A | $6.4m | Early VC | |
| N/A | $1.9m | Debt | |
$150m | Post IPO Equity | ||
| N/A | $75.0m | Post IPO Debt | |
| N/A | $25.0m | Post IPO Equity | |
| Total Funding | AUD16.5m | ||
Related Content
Recent News about Sorrento Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Sorrento Therapeutics
Edit
exited
ACQUISITION by Sorrento Therapeutics Jul 2020
ACQUISITION by Sorrento Therapeutics Feb 2022